460 related articles for article (PubMed ID: 30326033)
1. Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review.
; Parker C; Lewington V; Shore N; Kratochwil C; Levy M; Lindén O; Noordzij W; Park J; Saad F
JAMA Oncol; 2018 Dec; 4(12):1765-1772. PubMed ID: 30326033
[TBL] [Abstract][Full Text] [Related]
2. Radium-223 in the treatment of osteoblastic metastases: a critical clinical review.
Humm JL; Sartor O; Parker C; Bruland OS; Macklis R
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):898-906. PubMed ID: 25832684
[TBL] [Abstract][Full Text] [Related]
3. Targeted alpha therapy using Radium-223: From physics to biological effects.
Marques IA; Neves AR; Abrantes AM; Pires AS; Tavares-da-Silva E; Figueiredo A; Botelho MF
Cancer Treat Rev; 2018 Jul; 68():47-54. PubMed ID: 29859504
[TBL] [Abstract][Full Text] [Related]
4. Radium-223 in Metastatic Castration-Resistant Prostate Cancer: Clinical Development and Use in Contemporary Practice.
Morgan SC
J Med Imaging Radiat Sci; 2019 Dec; 50(4S1):S26-S30. PubMed ID: 31231006
[TBL] [Abstract][Full Text] [Related]
5. Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.
Gallicchio R; Mastrangelo PA; Nardelli A; Mainenti PP; Colasurdo AP; Landriscina M; Guglielmi G; Storto G
Tumori; 2019 Oct; 105(5):367-377. PubMed ID: 31096849
[TBL] [Abstract][Full Text] [Related]
6. Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride.
Pacilio M; Ventroni G; De Vincentis G; Cassano B; Pellegrini R; Di Castro E; Frantellizzi V; Follacchio GA; Garkavaya T; Lorenzon L; Ialongo P; Pani R; Mango L
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):21-33. PubMed ID: 26266887
[TBL] [Abstract][Full Text] [Related]
7. [Alpha emitter radium-223 dichloride: new therapy in castration-resistant prostate cancer with symptomatic bone metastases].
Heinzer H; König F; Klutmann S
Urologe A; 2014 Apr; 53(4):519-23. PubMed ID: 24604017
[TBL] [Abstract][Full Text] [Related]
8. [Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].
Tauber R; Gschwend J; Scheidhauer K; Eiber M; Krönke M
Urologe A; 2017 Jan; 56(1):24-31. PubMed ID: 28058455
[TBL] [Abstract][Full Text] [Related]
9. [Targeted radionuclide therapy for castration-resistant prostate cancer].
Nakamura K; Ohga S; Sasaki T; Baba S; Honda H
Nihon Rinsho; 2014 Dec; 72(12):2181-5. PubMed ID: 25518355
[TBL] [Abstract][Full Text] [Related]
10. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.
Poeppel TD; Handkiewicz-Junak D; Andreeff M; Becherer A; Bockisch A; Fricke E; Geworski L; Heinzel A; Krause BJ; Krause T; Mitterhauser M; Sonnenschein W; Bodei L; Delgado-Bolton RC; Gabriel M
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):824-845. PubMed ID: 29234845
[TBL] [Abstract][Full Text] [Related]
11. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
[TBL] [Abstract][Full Text] [Related]
12. Whole-Body and Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate Cancer Metastasis.
Abou DS; Ulmert D; Doucet M; Hobbs RF; Riddle RC; Thorek DL
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26683407
[TBL] [Abstract][Full Text] [Related]
13. Alpha and Beta Radiation for Theragnostics.
Song H; Sgouros G
PET Clin; 2024 Jul; 19(3):307-323. PubMed ID: 38688775
[TBL] [Abstract][Full Text] [Related]
14. Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer?
Dorff TB; Gross ME
Am Soc Clin Oncol Educ Book; 2015; ():e270-3. PubMed ID: 25993185
[TBL] [Abstract][Full Text] [Related]
15. Radium-223 dichloride in prostate cancer: proof of principle for the use of targeted alpha treatment in clinical practice.
Dizdarevic S; McCready R; Vinjamuri S
Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):192-217. PubMed ID: 31471713
[TBL] [Abstract][Full Text] [Related]
16. Nursing management of patients with castration-resistant prostate cancer undergoing radium-223 dichloride treatment.
Delacruz A; Arauz G; Curley T; Lindo A; Jensen T
Clin J Oncol Nurs; 2015 Apr; 19(2):E31-5. PubMed ID: 25840395
[TBL] [Abstract][Full Text] [Related]
17. Radium-223 dichloride in clinical practice: a review.
Florimonte L; Dellavedova L; Maffioli LS
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1896-909. PubMed ID: 27121689
[TBL] [Abstract][Full Text] [Related]
18. Nuclear Medicine Therapy With 223Radium-dichloride for Osseous Metastases in Prostate Carcinoma.
Wale DJ; Viglianti BL; Gross MD; Ferretti A; Rubello D; Wong KK
Am J Clin Oncol; 2019 Jan; 42(1):99-106. PubMed ID: 30204613
[TBL] [Abstract][Full Text] [Related]
19. Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.
McGann S; Horton ER
Ann Pharmacother; 2015 Apr; 49(4):469-76. PubMed ID: 25573268
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Metastatic Bone Disease and the Emerging Role of Radium-223.
Coleman R
Semin Nucl Med; 2016 Mar; 46(2):99-104. PubMed ID: 26897713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
